Spain· ES:1161146005
GLYXAMBI 10 MG/5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
A medicinal product containing linagliptina + empagliflozina, registered in Spain by Boehringer Ingelheim International Gmbh.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- linagliptina + empagliflozina
- Manufacturer
- Boehringer Ingelheim International Gmbh
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cima_codigo71651730EUR 92.26
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linagliptina + empagliflozina in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLYXAMBIBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- United StatesGlyxambiBoehringer Ingelheim Pharmaceuticals, Inc.
- SwitzerlandGlyxambi
- FinlandGlyxambiBoehringer Ingelheim International GmbH
- United KingdomGlyxambi 10mg/5mg tabletsBoehringer Ingelheim Ltd
- IrelandGlyxambi 10 mg/5 mg film-coated tabletsBoehringer Ingelheim International GmbH
- IcelandGlyxambiBoehringer Ingelheim International GmbH*
- NetherlandsGlyxambi 10 mg/ 5 mg, filmomhulde tablettenBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Glyxambi
- Liechtenstein · Glyxambi
- Norway · Glyxambi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b78f62d1-8183-4d38-b29b-c256d3eaa21a GET /v1/drugs/b78f62d1-8183-4d38-b29b-c256d3eaa21a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Medicamento Sujeto A Prescripción Médica",
"estado": "{\"aut\":1499724000000}",
"nregistro": "1161146005",
"substance": "linagliptina + empagliflozina"
}See everything about linagliptina + empagliflozina.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.